Which COVID-19 vaccine product provides superior efficacy for patients aged 65 years and older—Moderna Spikevax (mRNA‑1273) or the next‑generation mNEXSPIKE?

mNEXSPIKE provides superior efficacy for patients over 65 compared to Spikevax

For patients aged 65 years and older, mNEXSPIKE (mRNA-1283) is the recommended COVID-19 vaccine over Spikevax (mRNA-1273), based on its FDA approval specifically for this high-risk population and demonstrated superior real-world effectiveness.

Key Evidence Supporting mNEXSPIKE

The FDA has specifically approved mNEXSPIKE for individuals 65 years and older, as well as those 12-64 years with high-risk conditions 1. This targeted indication reflects regulatory recognition of its optimized benefit-risk profile in older adults.

Real-world effectiveness data from the 2025-2026 season demonstrates that mNEXSPIKE (mRNA-1283) achieved:

• 59.3% effectiveness against COVID-19-related hospitalization in adults ≥65 years
• 66.9% effectiveness in adults ≥75 years (the highest-risk subgroup)
• 42.0% effectiveness against medically attended COVID-19 in those ≥65 years 2

Comparative Performance

When directly compared to other vaccines, mRNA-1283 (the active component in mNEXSPIKE) showed:

• 31.7% greater effectiveness than protein-based vaccines against medically attended COVID-19
• 40.7% greater effectiveness against hospitalization with COVID-19
• In adults ≥65 specifically: 25.7% better protection against medically attended disease and 41.7% better protection against hospitalization 3

Safety Profile

The safety profile is consistent with previous mRNA formulations 1. Key considerations for patients ≥65:

Most common adverse reactions (≥10%):

• Pain at injection site (54.6%)
• Fatigue (43.0%)
• Headache (33.1%)
• Myalgia (30.5%)
• Arthralgia (25.7%)

Important caveat: Myocarditis/pericarditis risk is substantially lower in older adults compared to younger males. The estimated rate is approximately 8 cases per million doses in those 6 months-64 years, with the highest risk in males 12-24 years (27 per million) 1. This makes the benefit-risk calculation particularly favorable for the ≥65 population.

Clinical Algorithm for Vaccine Selection

For patients ≥65 years:

1. First-line recommendation: mNEXSPIKE (0.2 mL intramuscular dose)
2. Timing: At least 3 months after last COVID-19 vaccine dose 1
3. Contraindications to check:
   • Prior severe allergic reaction to any Moderna COVID-19 vaccine or mRNA vaccine
   • Known allergy to vaccine components 1

For patients 12-64 years:

• Use mNEXSPIKE only if they have at least one high-risk condition for severe COVID-19 1
• Otherwise, use standard Spikevax or other authorized vaccines per ACIP guidelines 4

Why This Matters for Mortality and Morbidity

The ≥65 age group experiences the highest rates of severe COVID-19, making vaccination most cost-effective in this population with an ICER of $23,308 per QALY 4. The superior effectiveness of mNEXSPIKE translates directly to:

• Reduced hospitalizations (the primary driver of mortality in this age group)
• Lower risk of severe disease complications including stroke
• Better quality of life through prevention of symptomatic illness

Common Pitfalls to Avoid

1. Don't delay vaccination waiting for a "better" vaccine—the current circulating variants make timely vaccination critical
2. Don't use mNEXSPIKE in patients <65 without high-risk conditions—it's not FDA-approved for this indication 1
3. Don't skip the 3-month interval after prior vaccination—this timing optimizes immune response 1
4. Don't dismiss vaccination due to myocarditis concerns in older adults—this risk is negligible in the ≥65 population and vastly outweighed by COVID-19 stroke and mortality risks 4, 1

The evidence consistently demonstrates that mNEXSPIKE provides superior protection against the outcomes that matter most—hospitalization and death—in the population most vulnerable to severe COVID-19.